Rona Therapeutics Files IND for RN3161, Novel siRNA Targeting INHBE for Obesity Treatment
核心洞察
Rona Therapeutics (搜索) has successfully submitted RN3161 (搜索) to the Australian Human Research Ethics Committee, marking a significant regulatory milestone for this GalNAc-conjugated siRNA targeting INHBE for obesity treatment.
The novel therapy demonstrated over 90% INHBE mRNA knockdown in preclinical monkey studies with a single low dose, potentially offering weight loss while preserving lean muscle mass.
RN3161 (搜索)'s long-lasting gene silencing enables dosing intervals of every 6 to 12 months, addressing adherence challenges that plague current obesity treatments.
Rona Therapeutics (搜索) announced the successful submission of RN3161 (搜索) to the Australian Human Research Ethics Committee (HREC), advancing a novel GalNAc-conjugated siRNA targeting INHBE for adults with overweight and obesity. The regulatory filing represents a significant milestone for the company's proprietary RNAi therapeutic platform and addresses critical unmet needs in obesity management.
Novel Mechanism Targets Fat Metabolism
RN3161 (搜索) targets the INHBE gene found in the liver, which produces Activin E (搜索), a protein that helps control fat metabolism. According to the company, people with certain INHBE gene changes demonstrate better fat distribution, body composition, healthier cholesterol levels, and lower risks of type 2 diabetes or heart disease, making INHBE a promising therapeutic target for improved obesity treatments.
The therapy was developed through Rona's proprietary GAIA™ platform and is engineered to reduce fat while preserving lean mass, distinguishing it from existing obesity treatments that often cause muscle loss alongside weight reduction.
Preclinical Efficacy and Dosing Advantages
In preclinical studies, RN3161 (搜索) demonstrated more than 90% INHBE mRNA knockdown in monkeys with a low single dose. The therapy is engineered with optimized GalNAc-conjugated delivery and chemical modifications designed to minimize off-target risks.
A key differentiator of RN3161 (搜索) is its long-lasting gene silencing capability, which supports dosing intervals of every 6 to 12 months (Q6M to Q12M). This extended dosing schedule could significantly enhance patient adherence and make the treatment more suitable for long-term obesity management, addressing a major challenge with current obesity therapies.
Addressing Treatment Limitations
Current obesity treatments often cause significant side effects, including nausea, vomiting and muscle loss, and are difficult to adhere to over time. RN3161 (搜索)'s mechanism of action and dosing profile are designed to address these limitations.
"The successful HREC submission of RN3161 (搜索) marks an exciting step in advancing a novel therapeutic to treat obesity," said Alex M. DePaoli, Chief Medical Officer. "RN3161 offers the potential benefit of losing weight with preserved muscle mass, but also the potential to enhance the metabolic benefits associated with fat loss. Further, infrequent dosing offers better adherence and weight loss maintenance. This represents a potential new paradigm in the field of obesity management."
Platform Validation and Future Outlook
RN3161 (搜索) represents the fourth clinical candidate from Rona's GAIA™ platform, demonstrating the company's consistent advancement of innovative RNAi medicines from bench to bedside. The successful regulatory submission underscores the platform's potential for developing durable therapeutic solutions.
"RN3161 (搜索) could maintain high quality weight loss post GLP-1 era," commented Stella Shi, CEO. "This milestone reflects our ambition to reshape the obesity treatment paradigm for healthier weight loss. It renews our mission to bring innovative and durable therapies to patients worldwide. We're committed to translating cutting-edge siRNA technologies into therapies in multiple areas."
Rona Therapeutics (搜索) is a pioneering RNAi platform company dedicated to addressing cardiometabolic diseases and obesity worldwide, with proprietary liver and extra-hepatic delivery platforms. The company has raised $100 million USD since inception.